Portugal as a global hub for healthcare innovation

The Champalimaud Foundation is developing digital therapies for neurodegenerative diseases such as Parkinson's and Alzheimer's; NOVA Medical School is developing products such as a hydrogel with antibacterial properties for topical application; and UC Business is collaborating with Bluepharma on a project for technological platforms for cancer treatment. These are just a few examples of the innovative projects being developed by these institutions.

Strategic partnerships with companies such as BIAL or AstraZeneca, and European consortia such as the Horizon Europe programmes, strengthen the national scientific ecosystem, increase competitiveness and position Portugal as a global innovation hub.

The Champalimaud Foundation develops innovative therapies in neuroscience and cancer, including digital treatments and cellular therapies. With a multicultural team and international partnerships, it aims to democratise access to scientific advances by developing affordable gene therapies.

Read more.

NOVA Medical School has invested in professionalising and creating services to support research. This commitment has led to increased participation in European consortia and the development of strategic partnerships with global institutions such as Harvard Medical School.

In the pharmaceutical industry, it has promoted an open ecosystem for co-creation, with notable partnerships with BIAL and AstraZeneca.

Read more.

UC Business, established by the University of Coimbra, promotes knowledge transfer and strategic partnerships with companies. In the pharmaceutical industry, initiatives such as the Bluepharma-UC Innovation Award and the CiNTech project support research leading to new products and services, highlighting the importance of collaboration between academia and industry in creating competitive innovation.

Read more.